BACKGROUND AND AIMS: Corticosteroids are widely used in managing inflammatory bowel disease (IBD). While adverse events (AEs) of corticosteroids are well recognized, current understanding of corticosteroid-related AE burden in IBD remains incomplete. METHODS: AE reports for prednisone/prednisolone and budesonide were extracted from the Food and Drug Administration Adverse Event Reporting System (FAERS) and VigiBase databases. Total and frequently reported AEs were tabulated, and AEs of special interest were compared with reports for all drugs using proportional reporting ratio criteria. Database reports were compared with AEs reported in a patient survey capturing corticosteroid exposure and AE recall. RESULTS: In FAERS and VigiBase, 344 140 and 42 836 AEs were reported, respectively, in patients with IBD
among these, 10 157 (3.0%) and 11 391 (26.6%), respectively, were related to prednisone/prednisolone or budesonide. AEs associated with corticosteroid use in IBD increased over time. Adrenal insufficiency, Cushingoid complications, osteonecrosis, osteoporosis, diabetes, and pancreatitis were disproportionately reported for corticosteroids. Among 9229 patients who responded to the survey, 6434 (69.7%) reported corticosteroid exposure. AEs were more frequently recalled by patients exposed to prednisone (61.9%) vs budesonide (27.4%
p = 0.0001). The most commonly recalled AEs differed from those reported in the pharmacovigilance databases and included weight gain, sleep problems, mood disturbance, and skin changes. Younger patients and those with mental health disorders were more likely to recall suicidal thoughts/attempts. CONCLUSIONS: Adverse events associated with IBD-related corticosteroid use were frequent. Patients reported AEs affecting quality of life, while clinicians disproportionately reported AEs based on objective diagnostic criteria.